@article{97dc417898c946c4ae36b0aa9ddc29df,
title = "Bipolar treatment efficacy - Authors' reply",
author = "Tomofumi Miura and Furukawa, \{Toshi A.\} and Andrea Cipriani and Keisuke Motomura and Hiroshi Mitsuyasu and Shiro Tanaka and Stefan Leucht and Satomi Shimano-Katsuki and Georgia Salanti and Hisashi Noma and Sarah Stockton and Geddes, \{John R.\} and Shigenobu Kanba",
note = "Funding Information: TM has received honoraria for lecture from GlaxoSmithKline, Eli Lilly Japan, Meiji Seika Pharma, Otsuka, Pfizer, Dainippon Sumitomo, Chugai Pharmaceutical and Mochida, and royalities from the Japan Council for Quality Health Care. TAF has received lecture fees from Eli Lilly, Meiji, Mochida, MSD, Pfizer and Tanabe-Mitsubishi; consultancy fees from Sekisui and Takeda Science Foundation; and royalties from Igaku-Shoin, Seiwa-Shoten and Nihon Bunka Kagaku-sha. KM has received grant or research support from Ono and Eli Lilly, and honoraria from Eli Lilly, Meiji Seika Pharma, Otsuka, Pfizer and Shionogi. HM has received honoraria from Mitsubishi Tanabe, Meiji Seika Pharma, GlaxoSmithKline, Pfizer, MSD, Astellas, Otsuka and Dainippon Sumitomo. ST has received honoraria from AstraZeneca, Ono Pharmaceutical, and CanBas, and grant or research support from Asahi Kasei Pharma and the Japanese Ministry of Health, Labour and Welfare. TM reports personal fees from GlaxoSmithCline, personal fees from Eli Lilly Japan, personal fees from Meiji Seika Pharma, personal fees from Otsuka, personal fees from Pfizer, personal fees from Mochida, personal fees from Dainippon Sumitomo, personal fees from Chugai Pharmaceutical, grants from JSPS KAKENHI, personal fees from Japan Council for Quality Health Care, outside the submitted work. SL has received honoraria for lectures from Abbvie, AstraZeneca, Bristol-Myers Squibb, ICON, Eli Lilly, Janssen, Johnson \& Johnson, Roche, Sanofi-Aventis, Lundbeck, and Pfizer; honoria for consulting or advisory boards from Roche, Eli Lilly, Medavante, Bristol-Myers Squibb, Alkermes, Janssen, Johnson \& Johnson and Lundbeck; and Eli Lilly has provided medication for a study with SL as primary investigator. HN has received a lecture fee from Boehringer Ingelheim and grants from the Japan Society of the Promotion of Science KAKENHI, the Japanese Ministry of the Environment, and the Japanese Ministry of Health, Labour and Welfare. JRG is an UK National Institute of Health Research senior investigator and chief investigator on the independent, UK Medical Research Council-funded CEQUEL trial, to which GlaxoSmithKline contributed the investigational drugs. SK has received honoraria from Pfizer, Janssen, GlaxoSmithKline, Eli Lilly Japan, Eisai, Meiji Seika Pharma, Taisho Toyama, Astellas, Ono, Mochida, Otsuka, Abott Japan, Shionogi, Dainippon Sumitomo, Nippon-Chemifa, Yoshitomiyakuhin, and MSD; and has received grant or research supports from Pfizer, Ono, GlaxoSmithKline, Astellas, Janssen, Yoshitomiyakuhin, Eli Lilly Japan, Otsuka, Mochida, Daiichi-Sankyo, Dainippon Sumitomo, Meiji Seika Pharma, Shionogi, Eisai and the Japanese Ministry of Health, Labour and Welfare. All other authors declare no competing interests.",
year = "2014",
month = nov,
day = "1",
doi = "10.1016/S2215-0366(14)00011-X",
language = "English",
volume = "1",
pages = "418--419",
journal = "The Lancet Psychiatry",
issn = "2215-0366",
publisher = "Elsevier Ltd.",
number = "6",
}
SDG 3 Good Health and Well-being